Teva Pharmaceutical Industries Ltd. plans to advance TEV-'408, an investigational anti-interleukin-15 monoclonal antibody, into a Phase 2b study for vitiligo in the fourth quarter of 2026. The decision follows encouraging results from an ongoing Phase 1b, open-label study in adults with active or stable non-segmental vitiligo (NSV), a chronic autoimmune disease causing loss of skin pigmentation. TEV-'408 is designed for convenient quarterly (Q12W) subcutaneous dosing and was well-tolerated with no safety signals observed to date.

Data from the Phase 1b study demonstrated improvements in skin pigmentation. At baseline, 66% of enrolled participants had vitiligo affecting more than 10% of body surface area. At week 24, in evaluable participants, nearly 75% reported improvement in facial vitiligo, with half reporting "much" or "very much" improved. Additionally, 42% achieved F-VASI50 and 21% achieved F-VASI75.

Key Phase 1b Efficacy Results at Week 24

Richard Francis, President and Chief Executive Officer of Teva, stated that TEV-'408 exemplifies the innovative programs the company is prioritizing to strengthen its immunology pipeline. He noted that the program reflects progress in the Pivot to Growth strategy and a commitment to differentiated innovation.

Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer at Teva, emphasized that the data strengthen confidence in the IL-15 pathway and highlight Teva's scientific expertise. TEV-'408 is also being evaluated for celiac disease in a Phase 2a study and was granted Fast Track designation by the U.S. FDA in May 2025. Teva’s agreement with Royalty Pharma provides up to $500 million of strategic R&D funding to accelerate the clinical research program of TEV-'408.

Teva Pharmaceutical Industries Ltd. has released its Q2 2026 Aide Memoire, compiled with public information previously provided by the company to assist investors ahead of its second quarter 2026 financial results. The document is available on the "Investors" page of Teva's website and is based on prior results, management's previous commentary about the business outlook, and data from select independent sources.

The company is scheduled to announce its Q2 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. A conference call and live webcast to discuss the results will follow later that day at 8:00 a.m. ET. Investors and analysts can access the webcast via Teva's investor relations website, while advance registration is required to participate in the conference call to obtain a phone number and personal PIN.

Teva Pharmaceutical Industries Ltd. is listed on the NYSE and TASE under the ticker symbol TEVA. The company operates as a biopharmaceutical firm, transforming into a leading innovative company enabled by a world-class generics business. For over 120 years, Teva has focused on neuroscience, immunology, and the provision of complex generic medicines, biosimilars, and pharmacy brands worldwide.

The announcement includes cautionary notes regarding forward-looking statements, which are based on management's current beliefs and expectations and are subject to risks and uncertainties. Factors that could cause actual results to differ include competitive pressures, execution of its Pivot to Growth strategy, significant indebtedness, and regulatory matters. These risks are detailed in Teva's Quarterly Report on Form 10-Q for the first quarter of 2026 and its Annual Report on Form 10-K for the year ended December 31, 2025.

Media inquiries can be directed to TevaCommunicationsNorthAmerica@tevapharm.com , while investor relations questions should be sent to TevaIR@Tevapharm.com .